Kevin A. Cassady
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
133
Citations
2,448
Est. group size
~8
Recurring co-author estimate
Active years
30
Publishing since 1997
Kevin A. Cassady's research focuses on using engineered viruses (oncolytic herpes simplex virus) to treat cancers such as glioma and malignant peripheral nerve sheath tumors, often in combination with immune-modulating drugs or CAR-T cell therapy. His work spans laboratory studies of how tumor cells resist viral infection, combination-therapy strategies, and mathematical modeling of treatment dynamics, as well as some public health surveillance work on pediatric influenza-related neurological complications.
Publication output was modest and fairly steady from 2017-2022, then rose sharply in 2023 before settling at a higher plateau through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Advanced inspection of nonplanar fiberoptic and photonic interfaces
2026
- Abstract A031: Early Immune Activation and Repair Cytokine Signatures Associate with Survival in Herpes-Based Oncolytic Virotherapy in Recurrent Glioma
Cancer Research · 2026
- Pediatric Influenza-Associated Encephalopathy and Acute Necrotizing Encephalopathy — United States, 2024–25 Influenza Season
MMWR Morbidity and Mortality Weekly Report · 2025
- CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma
Mathematical Biosciences · 2025
- CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Supplemental Cloning Methods from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Supplemental Tables and Figures from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Data from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Data from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023
- Data from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Supplemental Cloning Methods from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Supplemental Tables and Figures from STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
2023
- Supplementary Figure 3 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023
- Supplementary Figure 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023
- Supplementary Table 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
2023
- Molecular Therapy — Oncolytics×8
- Cancer Research×7
- Regular and Young Investigator Award Abstracts×7
- Frontiers in Immunology×4
- Viruses×3
- Jack Hedberg
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Roland W. Herzog
Biochemistry, Genetics and Molecular Biology · Indiana University
- Chelsea Bolyard
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kenneth Cornetta
Biochemistry, Genetics and Molecular Biology · Indiana University
- Nicholas Denton
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile